The A.I. story nobody is telling you (Read ASAP)

There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...

Click here to see Louis' new video for yourself.

Gregory DiNoia Biography and Net Worth

SVP of Mesa Laboratories

Greg DiNoia joined the Company in November 2017 as Senior Vice President. From 2008 through November 2017, Greg held several positions with Danaher Corporation (“Danaher”). During his Danaher tenure, Greg served as Global Vice President at Trojan Technologies, North American Vice President of Sales, Service and Customer Support at Hach, and Vice President and General Manager of North American Sales at Gilbarco Veeder Root all of which are wholly owned subsidiaries of Danaher. From 1997 to 2008, Greg was Vice President, Americas for Metrologic Instruments.

What is Gregory DiNoia's net worth?: The estimated net worth of Gregory DiNoia is at least $263,016.00 as of June 16th, 2021. Mr. DiNoia owns 2,529 shares of Mesa Laboratories stock worth more than $263,016 as of April 24th. This net worth approximation does not reflect any other investments that Mr. DiNoia may own. Learn More about Gregory DiNoia's net worth.
How do I contact Gregory DiNoia?: The corporate mailing address for Mr. DiNoia and other Mesa Laboratories executives is 12100 W 6TH AVE, LAKEWOOD CO, 80228. Mesa Laboratories can also be reached via phone at (303) 987-8000 and via email at [email protected]. Learn More on Gregory DiNoia's contact information.
Has Gregory DiNoia been buying or selling shares of Mesa Laboratories?: Gregory DiNoia has not been actively trading shares of Mesa Laboratories in the last ninety days. Most recently, Gregory Dinoia sold 280 shares of the business's stock in a transaction on Monday, November 8th. The shares were sold at an average price of $323.72, for a transaction totalling $90,641.60. Learn More on Gregory DiNoia's trading history.
Who are Mesa Laboratories' active insiders?: Mesa Laboratories' insider roster includes Brian Archbold (SVP), Gregory DiNoia (SVP), Evan Guillemin (Director), David Kelly (Director), Gary Owens (CEO), John Sakys (CFO), John Schmieder (Director), and John Sullivan (Director). Learn More on Mesa Laboratories' active insiders.
Are insiders buying or selling shares of Mesa Laboratories?: During the last twelve months, insiders at the medical instruments supplier sold shares 4 times. They sold a total of 7,500 shares worth more than $947,880.00. The most recent insider tranaction occured on December, 15th when SVP Brian David Archbold sold 1,500 shares worth more than $168,540.00. Insiders at Mesa Laboratories own 5.2% of the company. Learn More about insider trades at Mesa Laboratories.
Information on this page was last updated on 12/15/2023.

Gregory DiNoia Insider Trading History at Mesa Laboratories

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/8/2021	Sell	280	$323.72	$90,641.60
6/16/2021	Sell	1,211	$255.67	$309,616.37	2,529
6/4/2021	Sell	540	$260.27	$140,545.80	1,380
10/2/2020	Sell	332	$260.00	$86,320.00	1,452
9/4/2020	Sell	280	$243.55	$68,194.00	1,182
8/17/2020	Sell	835	$245.70	$205,159.50	2,297

Gregory DiNoia Buying and Selling Activity at Mesa Laboratories

Mesa Laboratories Company Overview

Mesa Laboratories, Inc. develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions. The Clinical Genomics segment develops, manufactures, and sells genetic analysis tools that include MassARRAY system and consumables, including chips, panels, and chemical reagent solutions used by clinical labs to perform genomic clinical testing in various therapeutic areas, such as screenings for hereditary diseases, pharmacogenetics, and oncology related applications. The Sterilization and Disinfection Control segment manufactures and sells biological, cleaning, and chemical indicators that are used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. This segment also provides testing and laboratory services primarily to the dental industry. The Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis and peptide synthesis solutions. This segment's solutions include protein analysis comprising analysis equipment, CDs, kits, and buffers; and peptide synthesizers that enable customers to automate chemical synthesis of peptides that are used in the creation of peptide therapies, biomaterials, cosmetics, and general research. The Calibration Solutions segment designs, manufactures, and markets quality control products to measure or calibrate temperature, pressure, pH, and humidity for health and safety purposes in the hospital, medical device manufacturing, pharmaceutical manufacturing, and various laboratory environments. This segment's products include continuous monitoring systems, dialysate meters and consumables, data loggers, gas flow calibration and air sampling equipment, and torque testing systems. The company was incorporated in 1982 and is headquartered in Lakewood, Colorado.

Today's Range

Now: $104.47

$103.26

$108.78

50 Day Range

MA: $104.92

$97.14

$114.10

2 Week Range

Now: $104.47

$82.86

$177.23

Volume

19,558 shs

Average Volume

48,105 shs

Market Capitalization

$563.51 million

P/E Ratio

614.57

Dividend Yield

0.64%

Beta

0.83